Wyss Center
VC Fund
Geneva, Switzerland
Wyss Center is a VC fund in Geneva focused on Medical and Manufacturing. Epios personalized and precision management of brain disorders using daily life monitoring and therapeutics. The Epios system comprises a series of thin leads incorporating sensing electrodes and a miniature implant, inserted beneath the skin. The neural signals are wirelessly transmitted to an external receiver held in place on the skin directlyover the implant with a magnet, and from there are conveyed to a wearable data processor and are finally securely stored in the Epios Cloud.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Wyss Center invests in
Stages Wyss Center invests in
Countries Wyss Center invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Grant
- $109k–$109k
Investment Focus
Industry
- Medical 2 (40%)
- Manufacturing 2 (40%)
- Medical Device 2 (40%)
- Fitness 1 (20%)
- Security 1 (20%)
Stage
- Seed 2 (40%)
- Grant 2 (40%)
- Series A 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erwin Böttinger
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Clee Medical believes the rapid growth of neurotech is constrained by inefficiencies in surgical tools and techniques. | Seed / Feb 25, 2026 | ||
Deegtal
|
dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone. | $1.1M / Seed / Dec 13, 2024 | |
| ARTIRIA Medical provides micro-actuated device allowing to treat vascular diseases. | $6M / Series A / Feb 27, 2024 | ||
Bearmind
|
Bearmind developing technology for monitoring and real-time analysis of head impact in athletes. | $109.3K / Grant / Sep 06, 2021 | |
| A mobile application to help people remember, understand and control their dreams. | $109.3K / Grant / Sep 06, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Wyss Center invest in?
Wyss Center invests primarily in Medical, Manufacturing and Medical Device startups, most often at Seed and Grant stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wyss Center's check size?
Wyss Center typically joins rounds of $109k–$109k at Grant. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wyss Center participates in.
How do I contact Wyss Center?
Public channels for Wyss Center include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wyss Center?
The team at Wyss Center includes Erwin Böttinger (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
